Home
Resources
Publications
Associations Between Disease Activity, Markers of HDL Functionality and Arterial Stiffness in Patients With Rheumatoid Arthritis

Associations Between Disease Activity, Markers of HDL Functionality and Arterial Stiffness in Patients With Rheumatoid Arthritis

Eliana Botta, Tomás Meroño, Carla Saucedo, Maximiliano Martín, Walter Tetzlaff, Patricia Sorroche, Laura Boero, Verónica Malah, Martín Menafra, Leonardo Gómez Rosso, John M Chapman, Anatol Kontush, Enrique Soriano, etc.

Atherosclerosis. 2016 Aug;251:438-444.

PMID: 27344073

Abstract:

Background and aims:
Rheumatoid arthritis (RA) is a chronic, inflammatory disease associated with increased risk of cardiovascular disease (CVD). Measures of HDL metabolism/function were shown to be altered in RA patients with high disease activity. We aimed at evaluating the effect of HDL characteristics on arterial stiffness in RA patients classified according to the inflammatory disease activity.
Methods:
RA patients were classified according to disease activity (DAS-28) into active RA (n = 27; DAS-28 > 3.2) and inactive RA patients (n = 17; DAS-28 < 3.2). A control group of healthy individuals was also studied (n = 33). Clinical and biochemical characteristics, cholesteryl ester transfer protein (CETP) and paraoxonase 1 (phenylacetate and paraoxonase) activities and carotid-femoral pulse wave velocity (cf-PWV) were determined.
Results:
Anthropometric characteristics were similar in all groups. In accordance with the inflammatory status, active RA patients presented elevated hsCRP levels (p < 0.001). There were no differences in the lipid profile between groups. Similarly, features of insulin resistance were absent in RA patients (p = non-significant). Active RA patients presented higher CETP activity than the other two groups (p = 0.026). Phenylacetate and paraoxonase activities were altered in active RA patients in comparison with the other groups (p = 0.034 and p = 0.041, respectively). Cf-PWV was significantly higher in active RA patients in comparison with controls, following adjustment by age (p = 0.030). Age (βst = 0.468, p = 0.013) and apo A-I levels (βst = -0.405, p = 0.029) were independent predictors of cf-PWV in a model including hsCRP, HOMA-IR, and phenylacetate activity (r(2) = 0.42).
Conclusions:
High DAS-28 identifies patients with alterations in HDL characteristics. Plasma levels of apo A-I can be used as a marker of arterial stiffness in RA.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP33998264	Cholesteryl phenylacetate		33998-26-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: